Detalles de la búsqueda
1.
Clinical Management of Adverse Events Associated with Lorlatinib.
Oncologist;
24(8): 1103-1110, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30890623
2.
Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.
Oncologist;
20(10): 1175-81, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26330460
3.
The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.
Bioorg Med Chem;
20(9): 2845-9, 2012 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22494842
4.
Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
J Manag Care Spec Pharm;
28(4): 435-448, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35100006
5.
Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.
Cancer Treat Res Commun;
31: 100555, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35421820
6.
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
J Med Econ;
24(sup1): 71-83, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34873975
7.
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer.
Drugs Real World Outcomes;
7(4): 261-269, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32725539
8.
Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners.
Adv Ther;
37(6): 3019-3030, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32399810
9.
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.
Lung Cancer (Auckl);
10: 11-20, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30804692
10.
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study.
J Clin Med;
7(6)2018 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29844259
11.
Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.
ACS Med Chem Lett;
5(6): 717-21, 2014 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24944750
12.
Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase.
ACS Med Chem Lett;
4(6): 509-13, 2013 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900701
13.
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.
ACS Med Chem Lett;
3(3): 252-6, 2012 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900461
14.
Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.
ACS Med Chem Lett;
2(12): 933-7, 2011 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900283
Resultados
1 -
14
de 14
1
Próxima >
>>